GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Skinvisible Inc (OTCPK:SKVI) » Definitions » Capex-to-Revenue

Skinvisible (Skinvisible) Capex-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 1999. Start your Free Trial

What is Skinvisible Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Skinvisible's Capital Expenditure for the three months ended in Dec. 2023 was $0.00 Mil. Its Revenue for the three months ended in Dec. 2023 was $0.01 Mil.

Hence, Skinvisible's Capex-to-Revenue for the three months ended in Dec. 2023 was 0.00.


Skinvisible Capex-to-Revenue Historical Data

The historical data trend for Skinvisible's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Skinvisible Capex-to-Revenue Chart

Skinvisible Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.61 0.06 0.03 0.01 0.45

Skinvisible Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.20 1.80 - -

Competitive Comparison of Skinvisible's Capex-to-Revenue

For the Household & Personal Products subindustry, Skinvisible's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Skinvisible's Capex-to-Revenue Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Skinvisible's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Skinvisible's Capex-to-Revenue falls into.



Skinvisible Capex-to-Revenue Calculation

Skinvisible's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.009) / 0.02
=0.45

Skinvisible's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0.005
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Skinvisible  (OTCPK:SKVI) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Skinvisible Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Skinvisible's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Skinvisible (Skinvisible) Business Description

Traded in Other Exchanges
N/A
Address
6320 South Sandhill Road, Suite 10, Las Vegas, NV, USA, 89120
Skinvisible Inc is a pharmaceutical research and development company that has developed and patented a polymer delivery system, Invisicare and formulated over forty topical skin products, which it out-licenses globally. Invisicare is a patented polymer delivery system that enhances the delivery of active ingredients for topically applied skin care products. Its patented technology has a formula and process for combining active ingredients with a delivery system that extends the duration of time the product remains on the skin and active.
Executives
St James David M director 3395 S. JONES BLVD., #169, LAS VEGAS NV 89146
Doreen Mcmorran 10 percent owner 6320 S. SANDHILL RD UNIT 10, LAS VEGAS NV 89120
Brian Piwek director 9014 GLENEAGLE DRIVE, BLAINE WA 98230
E Greg Mccartney director #307-15338 18TH AVENUE, SURREY BC A1 V4A 1W8
Jost Steinbruchel director 7, RUE DES BATTOIRS, POBOX #214, 1211 GENEVA 4 V8 000000
Robert F Lutz director, 10 percent owner
Terry Howlett director, 10 percent owner, officer: President & Chief Exec.Officer 6320 S. SANDHILL ROAD, SUITE #10, LAS VEGAS NV 89120
Skinvisible Inc director, 10 percent owner, officer: President 6320 S SANDHILL ROAD, SUITE 10, LAS VEGAS NV 89120
Lutz Family Trust 10 percent owner 8322 WEST TONTO LANE, PEORIA AZ 85382